Matches in SemOpenAlex for { <https://semopenalex.org/work/W4250106495> ?p ?o ?g. }
Showing items 1 to 57 of
57
with 100 items per page.
- W4250106495 endingPage "237" @default.
- W4250106495 startingPage "232" @default.
- W4250106495 abstract "In vitro-activated T lymphocytes can be retargeted with anti-CD3 × anti-tumor bispecific antibodies (BsAb) to kill tumor cells in vitro and in vivo. The purpose of the present study was to examine the systemic and intra-tumor effects of in vivo T-cell activation with BsAb, staphylococcal enterotoxin B (SEB), and β-glucan in combination with BsAb as a retargeting agent. CL-62 melanoma cells were injected subcutaneously into C3H/HeN mice. Mice were subsequently treated with BsAb alone or with SEB or β-glucan plus BsAb. Fresh splenocytes, lymph-node cells and tumor-infiltrating lymphocytes (TIL) were tested for their proliferative response using incorporation of 3H-thymidine, and for their ability to lyse CL-62 cells in the presence or absence of BsAb in 4-hr 51Chromium release assays. Toxicity of treatments was assessed in a D-galactosamine model. BsAb, alone or combined with β-glucan, had essentially no effect on systemic T-cell cytotoxicity, and essentially no effect on systemic proliferation, unless exogenous IL-2 was provided. At the tumor site, BsAb alone, BsAb plus β-glucan, and SEB plus BsAb all significantly increased BsAb-mediated TIL cytotoxicity. In contrast to the TIL-limited effects of BsAb and of BsAb plus β-glucan, SEB plus BsAb markedly increased both systemic and intra-tumor T-lymphocyte activation. Toxicity correlated with measures of systemic activation, with limited effects from BsAb alone and from β-glucan plus BsAb, and with marked lethality from SEB plus BsAb. Overall, these results suggest moderate intra-tumor activation of TIL, but no measurable systemic activation after in vivo treatment with BsAb or β-glucan plus BsAb. SEB plus BsAb results in complete T-cell activation in both systemic and intra-tumor compartments, but at the expense of increased systemic toxicity. In conclusion, TIL can be activated in situ with different combinations of in vivo activants. In vivo-activated TIL can be retargeted with bispecific antibodies to lyse tumor cells, and may be an alternative to ex vivo T-cell activation and adoptive transfer therapy. © 1996 Wiley-Liss, Inc." @default.
- W4250106495 created "2022-05-12" @default.
- W4250106495 creator A5001572155 @default.
- W4250106495 creator A5010829414 @default.
- W4250106495 creator A5034986366 @default.
- W4250106495 date "1996-07-17" @default.
- W4250106495 modified "2023-09-26" @default.
- W4250106495 title "Tumor‐infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab′)2 bispecific antibodies" @default.
- W4250106495 doi "https://doi.org/10.1002/(sici)1097-0215(19960717)67:2<232::aid-ijc14>3.3.co;2-1" @default.
- W4250106495 hasPublicationYear "1996" @default.
- W4250106495 type Work @default.
- W4250106495 citedByCount "0" @default.
- W4250106495 crossrefType "journal-article" @default.
- W4250106495 hasAuthorship W4250106495A5001572155 @default.
- W4250106495 hasAuthorship W4250106495A5010829414 @default.
- W4250106495 hasAuthorship W4250106495A5034986366 @default.
- W4250106495 hasBestOaLocation W42501064951 @default.
- W4250106495 hasConcept C109316439 @default.
- W4250106495 hasConcept C150903083 @default.
- W4250106495 hasConcept C185592680 @default.
- W4250106495 hasConcept C202751555 @default.
- W4250106495 hasConcept C203014093 @default.
- W4250106495 hasConcept C207001950 @default.
- W4250106495 hasConcept C502942594 @default.
- W4250106495 hasConcept C55493867 @default.
- W4250106495 hasConcept C71924100 @default.
- W4250106495 hasConcept C86803240 @default.
- W4250106495 hasConceptScore W4250106495C109316439 @default.
- W4250106495 hasConceptScore W4250106495C150903083 @default.
- W4250106495 hasConceptScore W4250106495C185592680 @default.
- W4250106495 hasConceptScore W4250106495C202751555 @default.
- W4250106495 hasConceptScore W4250106495C203014093 @default.
- W4250106495 hasConceptScore W4250106495C207001950 @default.
- W4250106495 hasConceptScore W4250106495C502942594 @default.
- W4250106495 hasConceptScore W4250106495C55493867 @default.
- W4250106495 hasConceptScore W4250106495C71924100 @default.
- W4250106495 hasConceptScore W4250106495C86803240 @default.
- W4250106495 hasIssue "2" @default.
- W4250106495 hasLocation W42501064951 @default.
- W4250106495 hasOpenAccess W4250106495 @default.
- W4250106495 hasPrimaryLocation W42501064951 @default.
- W4250106495 hasRelatedWork W1592261125 @default.
- W4250106495 hasRelatedWork W1982027601 @default.
- W4250106495 hasRelatedWork W200909032 @default.
- W4250106495 hasRelatedWork W2083651068 @default.
- W4250106495 hasRelatedWork W2088196762 @default.
- W4250106495 hasRelatedWork W2416964709 @default.
- W4250106495 hasRelatedWork W2464301138 @default.
- W4250106495 hasRelatedWork W2517050254 @default.
- W4250106495 hasRelatedWork W2793519975 @default.
- W4250106495 hasRelatedWork W2188252428 @default.
- W4250106495 hasVolume "67" @default.
- W4250106495 isParatext "false" @default.
- W4250106495 isRetracted "false" @default.
- W4250106495 workType "article" @default.